On May 17th, Cloudbreak Pharma Inc. (Cloudbreak) and Centre for Eye and Vision Research Ltd. (CEVR) signed a memorandum of understanding for strategic cooperation at the Asia Summit on Global Health (ASGH) in Hong Kong. The parties intend to explore opportunities to collaborate on research in ocular science and have reached a preliminary understanding of the framework.
Cloudbreak operates a capital-efficient business model to develop safe and effective treatment for eye diseases. We quickly advance drug candidates to complete proof-of-concept (POC) clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC, and clinical development to maximize capital for drug development efficiently. Cloudbreak has multiple clinical-stage pipelines targeting pterygium (Phase 3), meibomian gland dysfunction, pinguecula and preventing juvenile myopia progression.
CEVR is a research collaboration between The Hong Kong Polytechnic University and the University of Waterloo in Canada under the InnoHK initiative of the HKSAR Government. The CEVR aims to promote eye health through clinical, fundamental, and applied research, develop ground-breaking technologies to prevent vision loss and preserve sight among the aging population. The philosophy and research direction of CEVR highly align with Cloudbreak’s CBT-006 clinical pipeline, and the parties will collaborate on related research areas.
The Hong Kong Trade Development Council (HKTDC) facilitated the collaboration between Cloudbreak and CEVR, which marked Cloudbreak’s inaugural foray into developing clinical pipelines in Hong Kong. We believe Hong Kong’s solid research and development capabilities, extensive technological infrastructure, robust legal system, and intellectual property protection, as well as policy support for innovation and technology, and a world-class talent pool, make it an unparalleled base for global scientists, innovators, entrepreneurs, and investors to transform their ideas into tangible success. Furthermore, we aspire to bring more clinical trial pipelines to Hong Kong to expedite and enhance breakthroughs, broaden clinical research, and help people Seeing Life Better Through Medicine.
